Gerben van ‘t Klooster

1.1k total citations
15 papers, 885 citations indexed

About

Gerben van ‘t Klooster is a scholar working on Infectious Diseases, Oncology and Virology. According to data from OpenAlex, Gerben van ‘t Klooster has authored 15 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 5 papers in Oncology and 4 papers in Virology. Recurrent topics in Gerben van ‘t Klooster's work include HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Gerben van ‘t Klooster is often cited by papers focused on HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Gerben van ‘t Klooster collaborates with scholars based in Belgium, Netherlands and Germany. Gerben van ‘t Klooster's co-authors include Lieven Baert, Marie‐Paule Bouche, P. Van Remoortere, Herman Borghys, Laurent Schueller, Jan Rosier, René Galien, Piet Wigerinck, Herman de Kock and Paul Stevens and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Gerben van ‘t Klooster

15 papers receiving 857 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gerben van ‘t Klooster Belgium 10 331 227 180 162 147 15 885
Carol Braun Trapnell United States 15 202 0.6× 113 0.5× 163 0.9× 20 0.1× 25 0.2× 23 708
Federico Martini Italy 25 296 0.9× 368 1.6× 334 1.9× 12 0.1× 88 0.6× 68 1.6k
Muhammad Baluom United States 17 91 0.3× 24 0.1× 56 0.3× 196 1.2× 19 0.1× 20 781
R W Klecker United States 11 634 1.9× 478 2.1× 273 1.5× 19 0.1× 55 0.4× 14 1.4k
Tot Bui United States 15 199 0.6× 164 0.7× 50 0.3× 33 0.2× 14 0.1× 30 749
Tianyu He China 17 208 0.6× 313 1.4× 158 0.9× 49 0.3× 33 0.2× 52 839
Ronald B. Faanes United States 14 508 1.5× 446 2.0× 208 1.2× 10 0.1× 36 0.2× 35 1.6k
Mirjam Kuipers Netherlands 15 131 0.4× 63 0.3× 143 0.8× 28 0.2× 27 0.2× 27 647
Joshua O. Ojwang United States 14 263 0.8× 176 0.8× 110 0.6× 18 0.1× 17 0.1× 21 996
Hadas Dvory‐Sobol United States 31 1.0k 3.1× 355 1.6× 2.0k 11.3× 35 0.2× 2.2k 15.2× 98 3.1k

Countries citing papers authored by Gerben van ‘t Klooster

Since Specialization
Citations

This map shows the geographic impact of Gerben van ‘t Klooster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerben van ‘t Klooster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerben van ‘t Klooster more than expected).

Fields of papers citing papers by Gerben van ‘t Klooster

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerben van ‘t Klooster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerben van ‘t Klooster. The network helps show where Gerben van ‘t Klooster may publish in the future.

Co-authorship network of co-authors of Gerben van ‘t Klooster

This figure shows the co-authorship network connecting the top 25 collaborators of Gerben van ‘t Klooster. A scholar is included among the top collaborators of Gerben van ‘t Klooster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerben van ‘t Klooster. Gerben van ‘t Klooster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Vanhoutte, Frédéric, Minodora Mazur, Mykola Stanislavchuk, et al.. (2017). Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Arthritis & Rheumatology. 69(10). 1949–1959. 61 indexed citations
2.
Vanhoutte, Frédéric, Sonia Dupont, Roland Blanqué, et al.. (2015). P612. Human safety, pharmacokinetics and pharmacodynamics of the GPR84 antagonist GLPG1205, a potential new approach to treat IBD.. Journal of Crohn s and Colitis. 9(suppl 1). S387–S387. 3 indexed citations
3.
Vanhoutte, Frédéric, Sonia Dupont, Wouter Haazen, et al.. (2014). DOP070 The FFA2 antagonist GLPG0974: opportunity to treat neutrophil-driven inflammation. Journal of Crohn s and Colitis. 8. S48–S48. 1 indexed citations
4.
Vanhoutte, Frédéric, Annegret Van der Aa, Luc Meuleners, & Gerben van ‘t Klooster. (2013). THU0229 Safety and Efficacy of GLPG0634, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis: Results of a 4-Week Phase II a Dose Ranging, Multi-Center Trial. Annals of the Rheumatic Diseases. 72. A242–A242. 1 indexed citations
5.
Rompaey, Luc Van, René Galien, Ellen M. van der Aar, et al.. (2013). Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases. The Journal of Immunology. 191(7). 3568–3577. 181 indexed citations
6.
Namour, Florence, René Galien, Frédéric Vanhoutte, Piet Wigerinck, & Gerben van ‘t Klooster. (2013). THU0236 Once-Daily Dosing of GLPG0634, a Selective JAK1 Inhibitor, is Supported by Its Active Metabolite. Annals of the Rheumatic Diseases. 72. A244–A245. 1 indexed citations
7.
Gyseghem, Elke Van, Lieven Baert, P. Van Remoortere, et al.. (2010). Co-administration of darunavir and a new pharmacokinetic booster: Formulation strategies and evaluation in dogs. European Journal of Pharmaceutical Sciences. 41(2). 193–200. 6 indexed citations
8.
Klooster, Gerben van ‘t, et al.. (2010). Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation. Antimicrobial Agents and Chemotherapy. 54(5). 2042–2050. 159 indexed citations
9.
Thommes, Markus, Lieven Baert, Gerben van ‘t Klooster, et al.. (2009). Improved bioavailability of darunavir by use of κ-carrageenan versus microcrystalline cellulose as pelletisation aid. European Journal of Pharmaceutics and Biopharmaceutics. 72(3). 614–620. 23 indexed citations
10.
Baert, Lieven, Gerben van ‘t Klooster, Koen Iterbeke, et al.. (2009). Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. European Journal of Pharmaceutics and Biopharmaceutics. 72(3). 502–508. 185 indexed citations
11.
Reesink, H. W., Gregory Fanning, Christine J. Weegink, et al.. (2009). Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients. Gastroenterology. 138(3). 913–921. 123 indexed citations
12.
Visser, M.R., Lieven Baert, Gerben van ‘t Klooster, et al.. (2009). Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240. European Journal of Pharmaceutics and Biopharmaceutics. 74(2). 233–238. 42 indexed citations
13.
Gyseghem, Elke Van, Lieven Baert, Jan Rosier, et al.. (2008). Powder for reconstitution of the anti-HIV-1 drug TMC278 – Formulation development, stability and animal studies. European Journal of Pharmaceutics and Biopharmaceutics. 70(3). 853–860. 15 indexed citations
14.
Reesink, Hendrik W., René Verloes, Christine J. Weegink, et al.. (2008). 64 SAFETY OF THE HCV PROTEASE INHIBITOR TMC435350 IN HEALTHY VOLUNTEERS AND SAFETY AND ACTIVITY IN CHRONIC HEPATITIS C INFECTED INDIVIDUALS: A PHASE I STUDY. Journal of Hepatology. 48. S28–S29. 16 indexed citations
15.
Rakhmanova, Aza, A. A. Yakovlev, Monika Peeters, et al.. (2003). A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS. 17(17). 2487–2494. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carol Braun Trapnell Breakdown of academic impact, for papers by Federico Martini Breakdown of academic impact, for papers by Muhammad Baluom Breakdown of academic impact, for papers by R W Klecker Breakdown of academic impact, for papers by Tot Bui Breakdown of academic impact, for papers by Tianyu He Breakdown of academic impact, for papers by Ronald B. Faanes Breakdown of academic impact, for papers by Mirjam Kuipers Breakdown of academic impact, for papers by Joshua O. Ojwang Breakdown of academic impact, for papers by Hadas Dvory‐Sobol
Rankless by CCL
2026